Mabwell (Shanghai) Bioscience Co. Ltd. announced that its Cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC), 7MW-4911, has received IND clearance to initiate clinical trials from both the U.S. FDA and China's National Medical Products Administration (NMPA).
The efficacy of camptothecin-based topoisomerase I (Topo1) inhibitors, which are widely used as anticancer therapies, is often limited by resistance mechanisms, primarily involving mutations in the Topo1 enzyme and increased drug efflux mediated by ATP-binding cassette (ABC) transporters, particularly ABCG2 (BCRP).
Innate Pharma SA has obtained IND clearance from the FDA for IPH-4502, its novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) conjugated to exatecan targeting Nectin-4 in solid tumors. In nonclinical models, IPH-45 was well tolerated and showed antitumor efficacy in vitro and in vivo.
The lively antibody-drug conjugate (ADC) space chalked another collaboration as Taipei, Taiwan-based Foreseen Biotechnology Co. Ltd. scored a global licensing agreement worth as much as $1.03 billion with Ipsen SA, of Paris, for antibody-drug conjugate FS-001, which is said to bear first-in-class potential. The drug takes aim at a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role in tumor proliferation and metastasis, the companies said.
The lively antibody-drug conjugate (ADC) space chalked another collaboration as Taipei, Taiwan-based Foreseen Biotechnology Co. Ltd. scored a global licensing agreement worth as much as $1.03 billion with Ipsen SA, of Paris, for antibody-drug conjugate FS-001, which is said to bear first-in-class potential. The drug takes aim at a novel tumor-associated antigen that is overexpressed in many solid tumors and plays a critical role in tumor proliferation and metastasis, the companies said.
SN Bioscience Co. Ltd., headquartered in Seongnam-si, Gyeonggi-do’s second Pangyo Valley, gained U.S. FDA fast track designation for SNB-101 (SN-38), its new polymer nanoparticle cancer drug candidate for small-cell lung cancer.
SN Bioscience Co. Ltd., headquartered in Seongnam-si, Gyeonggi-do’s second Pangyo Valley, gained U.S. FDA fast track designation for SNB-101 (SN-38), its new polymer nanoparticle cancer drug candidate for small-cell lung cancer.
DNA topoisomerase I (TOP1) is an enzyme that has a direct role in transcriptional regulation, and thus has an impact on cell growth and may be considered a therapeutic target for cancer treatment. Previous research showed that high concentration release of nitric oxide (NO) together with TOP1 inhibition may be an effective strategy in promoting tumor cell apoptosis.
Gibson Oncology LLC and Purdue Research Foundation have synthesized DNA topoisomerase I (Topo1) inhibitors and/or Myc proto-oncogene protein promoter G-quadruplex (MycG4) ligands reported to be useful for the treatment of cancer.
Researchers from Astrazeneca plc described the development and preclinical evaluation of AZD-5335, a novel antibody-drug conjugate (ADC) consisting of folate receptor α (FR-α)-targeting antibody conjugated to a proprietary topoisomerase 1 inhibitor (TOP1i), being developed as a potential new therapeutic against ovarian cancer.
